Literature DB >> 26034112

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

Martin Dreyling1, Simone Ferrero2.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26034112      PMCID: PMC4450615          DOI: 10.3324/haematol.2015.127472

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.

Authors:  P M Banks; J Chan; M L Cleary; G Delsol; C De Wolf-Peeters; K Gatter; T M Grogan; N L Harris; P G Isaacson; E S Jaffe
Journal:  Am J Surg Pathol       Date:  1992-07       Impact factor: 6.394

2.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

Authors:  Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann
Journal:  Blood       Date:  2004-12-09       Impact factor: 22.113

3.  Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  M Dreyling; C Geisler; O Hermine; H C Kluin-Nelemans; S Le Gouill; S Rule; O Shpilberg; J Walewski; M Ladetto
Journal:  Ann Oncol       Date:  2014-09       Impact factor: 32.976

4.  Cytological and functional criteria for the classification of malignant lymphomata.

Authors:  K Lennert; H Stein; E Kaiserling
Journal:  Br J Cancer Suppl       Date:  1975-03

Review 5.  New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?

Authors:  Martin Dreyling; Simone Ferrero; Niklas Vogt; Wolfram Klapper
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

Review 6.  Current regimens and novel agents for mantle cell lymphoma.

Authors:  Yiming Chen; Michael Wang; Jorge Romaguera
Journal:  Br J Haematol       Date:  2014-06-28       Impact factor: 6.998

Review 7.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

8.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.

Authors:  Lena Nordström; Sandra Sernbo; Patrik Eden; Kirsten Grønbaek; Arne Kolstad; Riikka Räty; Marja-Liisa Karjalainen; Christian Geisler; Elisabeth Ralfkiaer; Christer Sundström; Anna Laurell; Jan Delabie; Mats Ehinger; Mats Jerkeman; Sara Ek
Journal:  Br J Haematol       Date:  2014-03-29       Impact factor: 6.998

10.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

Authors:  Sílvia Beà; Rafael Valdés-Mas; Alba Navarro; Itziar Salaverria; David Martín-Garcia; Pedro Jares; Eva Giné; Magda Pinyol; Cristina Royo; Ferran Nadeu; Laura Conde; Manel Juan; Guillem Clot; Pedro Vizán; Luciano Di Croce; Diana A Puente; Mónica López-Guerra; Alexandra Moros; Gael Roue; Marta Aymerich; Neus Villamor; Lluís Colomo; Antonio Martínez; Alexandra Valera; José I Martín-Subero; Virginia Amador; Luis Hernández; Maria Rozman; Anna Enjuanes; Pilar Forcada; Ana Muntañola; Elena M Hartmann; María J Calasanz; Andreas Rosenwald; German Ott; Jesús M Hernández-Rivas; Wolfram Klapper; Reiner Siebert; Adrian Wiestner; Wyndham H Wilson; Dolors Colomer; Armando López-Guillermo; Carlos López-Otín; Xose S Puente; Elías Campo
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

View more
  1 in total

1.  A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Authors:  Guillem Clot; Pedro Jares; Eva Giné; Alba Navarro; Cristina Royo; Magda Pinyol; David Martín-Garcia; Santiago Demajo; Blanca Espinet; Antonio Salar; Ana Ferrer; Ana Muntañola; Marta Aymerich; Hilka Rauert-Wunderlich; Elaine S Jaffe; Joseph M Connors; Randy D Gascoyne; Jan Delabie; Armando López-Guillermo; German Ott; George W Wright; Louis M Staudt; Andreas Rosenwald; David W Scott; Lisa M Rimsza; Sílvia Beà; Elías Campo
Journal:  Blood       Date:  2018-05-16       Impact factor: 25.476

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.